Concise review: Stem cells as an emerging platform for antibody therapy of cancer

Stem Cells

Volumn 28, Issue 11, 2010, Pages 2084-2087

  Frank, Richard T ^a   Najbauer, Joseph ^a   Aboody, Karen S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Carcinoembryonic antigen; Antibody; Blood brain barrier; Cancer therapy; CD3; Diabody; EGFR; HER2; Mesenchymal stem cells; Neural stem cells; scFv

Indexed keywords

ANTIBODY; CYTOKINE; CYTOSINE DEAMINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH FACTOR; HEME OXYGENASE 1; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; SCLEROPROTEIN; TRASTUZUMAB;

ANTIBODY PRODUCTION; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER THERAPY; CELL LINEAGE; CELL PROLIFERATION; CELL SURVIVAL; CELL THERAPY; DRUG BLOOD LEVEL; GLIOMA CELL; HUMAN; IMMUNOGENICITY; MESENCHYMAL STEM CELL; NEURAL STEM CELL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; STEM CELL; TUMOR LOCALIZATION; TUMOR VOLUME;

ANIMALS; ANTIBODIES; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; STEM CELLS;

EID: 78649823969     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.513     Document Type: Review

References (26)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-1157.
2. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343-357.
3. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 2008;15:739-752.
4. Najbauer J, Danks MK, Schmidt NO et al. Neural stem cell-mediated therapy of primary and metastatic solid tumors. In: Bertolotti R, Ozawa K, eds. Progress in Gene Therapy, Autologous and Cancer Stem Cell Gene Therapy. Singapore: World Scientific, 2007:335-372.
5. Kendall SE, Najbauer J, Johnston HF et al. Neural stem cell targeting of glioma is dependent on phosphoinositide 3-kinase signaling. Stem Cells 2008;26:1575-1586.
6. Zhao D, Najbauer J, Garcia E et al. Neural stem cell tropism to glioma: Critical role of tumor hypoxia. Mol Cancer Res 2008;6:1819-1829.
7. Frank RT, Edmiston M, Kendall SE et al. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. Plos One 2009;4:e8314.
8. Balyasnikova IV, Franco-Gou R, Mathis JM et al. Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface. J Tissue Eng Regen Med 2010;4:247-258.
9. Balyasnikova IV, Ferguson SD, Sengupta S et al. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. Plos One 2010;5:e9750.
10. Compte M, Cuesta AM, Sanchez-Martin D et al. Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds. Stem Cells 2009;27:753-760.
11. Wu AM, Senter PD. Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-1146.
12. Ubiali F, Nava S, Nessi V et al. Allorecognition of human neural stem cells by peripheral blood lymphocytes despite low expression of MHC molecules: Role of TGF-beta in modulating proliferation. Int Immunol 2007;19:1063-1074.
13. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726-736.
14. Mammolenti M, Gajavelli S, Tsoulfas P et al. Absence of major histocompatibility complex class I on neural stem cells does not permit natural killer cell killing and prevents recognition by alloreactive cytotoxic T lymphocytes in vitro. Stem Cells 2004;22:1101-1110.
15. Patel SA, Meyer JR, Greco SJ et al. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: Role of mesenchymal stem cell-derived TGF-beta. J Immunol 2010;184:5885-5894.
16. Hori J, Ng TF, Shatos M et al. Neural progenitor cells lack immunogenicity and resist destruction as allografts. Stem Cells 2003;21:405-416.
17. Wennersten A, Holmin S, Al Nimer F et al. Sustained survival of xenografted human neural stem/progenitor cells in experimental brain trauma despite discontinuation of immunosuppression. Exp Neurol 2006;199:339-347.
18. Mangi AA, Noiseux N, Kong D et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9:1195-1201.
19. Lee HJ, Kim MK, Kim HJ et al. Human neural stem cells genetically modified to overexpress Akt1 provide neuroprotection and functional improvement in mouse stroke model. Plos One 2009;4:e5586.
20. Tang YL, Tang Y, Zhang YC et al. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol 2005;46:1339-1350. (Pubitemid 41615559)
21. Lee EM, Kim JY, Cho BR et al. Down-regulation of MHC class I expression in human neuronal stem cells using viral stealth mechanism. Biochem Biophys Res Commun 2005;326:825-835.
22. Mishra PJ, Mishra PJ, Glod JW et al. Mesenchymal stem cells: Flip side of the coin. Cancer Res 2009;69:1255-1258.
23. Studeny M, Marini FC, Dembinski JL et al. Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593-1603.
24. Zischek C, Niess H, Ischenko I et al. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg 2009;250:747-753.
25. Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 2007;1:39-49.
26. Lin D, Najbauer J, Salvaterra PM et al. Novel method for visualizing and modeling the spatial distribution of neural stem cells within intracranial glioma. Neuroimage 2007;37 (suppl 1):S18-S26.